Ground-breaking innovation through use of Ciliates for efficient, safe and cost-effective production of biopharmaceuticals. Cilian is working on the development of better, highly effective antibodies against cancer. Cilian uses therapeutic enzymes from Ciliates for the treatment of pancreatic insufficiency. Cilian offers a solution to the threat of flu pandemics with a new method for rapid production of recombinant influenza vaccines. Cilian uses Ciliates of the genus.

Mit der Nutzung von Ciliaten geht Cilian neue Wege in der sicheren und kostengünstigen Herstellung hochwirksamer Medikamente. Cilian arbeitet an der Entwicklung neuer, hoch wirksamer Antikörper gegen Krebs. Cilian nutzt therapeutische Enzyme aus Ciliaten zur Behandlung der Pankreasinsuffizienz. Cilian bietet eine Lösung für die Bedrohung durch Grippe-Pandemien mit einem neuen Verfahren zur schnelleren Herstellung von rekombinanten Grippeimpfstoffen. Cilian publiziert Artikel in mAbs.

The COEBP is an interdisciplinary research centre initiated by support from the European Regional Development Fund and the North West Regional Development Agency. Led by Professor Alan Dickson, our Centre brings internationally recognised expertise together to accelerate the development and certainty in the production, harvest and utilisation of biopharmaceuticals.

Our Distributors in the world. Alcyon SFC Column is launched. Product Name Change of YMC CHIRAL Polysaccharide Derivative Series. Triart C18 ExRS is launched. Core-shell columns for UHPLC and HPLC Meteoric Core is launched.